Gilead Receives Approval in Canada for BIKTARVY™ (bictegravir, emtricitabine, tenofovir alafenamide) for the Treatment of HIV-1 Infection[From OttawaCitizen, July 12, 2018]
“MISSISSAUGA, Ontario — Gilead Sciences Canada, Inc. (Gilead Canada) today announced that Health Canada has granted a Notice of Compliance (NOC) for Biktarvy™ (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF), a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection. BIKTARVY combines the potency of a novel integrase strand transfer inhibitor (INSTI) bictegravir, with the demonstrated safety and efficacy profile of the Descovy® (FTC/TAF) dual nucleoside reverse transcriptase inhibitor (NRTI) backbone, and is the smallest INSTI-based triple-therapy STR available. BIKTARVY is Gilead’s third DESCOVY-based STR approved in Canada in the past three years.”
For more, click here.